{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T16:04:10Z","timestamp":1766678650866,"version":"3.40.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05644-y","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T02:01:37Z","timestamp":1720231297000},"page":"2327-2336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8290-1846","authenticated-orcid":false,"given":"Ana","family":"Urruticoechea-Arana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"\u00c1lvarez-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8822-9843","authenticated-orcid":false,"given":"Maria Luz","family":"Garc\u00eda-Vivar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-8185","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Pinto-Tasende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0358-6070","authenticated-orcid":false,"given":"Mar\u00eda Jes\u00fas","family":"Garc\u00eda de Y\u00e9benes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-2551","authenticated-orcid":false,"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-7145","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Queiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"issue":"1","key":"5644_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS (2017) Psoriatic arthritis: state of the art review. Clin Med (Lond) 17(1):65\u201370. https:\/\/doi.org\/10.7861\/clinmedicine.17-1-65","journal-title":"Clin Med (Lond)"},{"issue":"10136","key":"5644_CR2","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","volume":"391","author":"F Van den Bosch","year":"2018","unstructured":"Van den Bosch F, Coates L (2018) Clinical management of psoriatic arthritis. Lancet 391(10136):2285\u20132294. https:\/\/doi.org\/10.1016\/S0140-6736(18)30949-8","journal-title":"Lancet"},{"issue":"6","key":"5644_CR3","doi-asserted-by":"publisher","first-page":"e0234556","DOI":"10.1371\/journal.pone.0234556","volume":"15","author":"A Romero Perez","year":"2020","unstructured":"Romero Perez A, Queiro R, Seoane-Mato D, Graell E, Chamizo E, Chaves Chaparro L et al (2020) Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. PLoS ONE 15(6):e0234556. https:\/\/doi.org\/10.1371\/journal.pone.0234556","journal-title":"PLoS ONE"},{"issue":"10","key":"5644_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD, Psoriatic Arthritis (2017) N Engl J Med 376(10):957\u201370. https:\/\/doi.org\/10.1056\/NEJMra1505557.","journal-title":"N Engl J Med"},{"issue":"1","key":"5644_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM, Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3(1):55\u201378. https:\/\/doi.org\/10.1016\/0049-0172(73)90035-8","journal-title":"Semin Arthritis Rheum"},{"key":"5644_CR6","doi-asserted-by":"publisher","unstructured":"Coates LC, Corp N, van der Windt DA, Soriano ER, Kavanaugh A (2021) GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. J Rheumatol Suppl. 97:65\u2009\u2013\u20096. https:\/\/doi.org\/10.3899\/jrheum.201681","DOI":"10.3899\/jrheum.201681"},{"issue":"11","key":"5644_CR7","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1007\/s10067-021-05774-9","volume":"40","author":"CG Gialouri","year":"2021","unstructured":"Gialouri CG, Fragoulis GE (2021) Disease activity indices in psoriatic arthritis: current and evolving concepts. Clin Rheumatol 40(11):4427\u20134435. https:\/\/doi.org\/10.1007\/s10067-021-05774-9","journal-title":"Clin Rheumatol"},{"issue":"10","key":"5644_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ad.2017.07.002","volume":"108","author":"M Llamas-Velasco","year":"2017","unstructured":"Llamas-Velasco M, de la Cueva P, Notario J, Martinez-Pilar L, Martorell A, Moreno-Ramirez D (2017) Moderate psoriasis: a proposed definition. Actas Dermosifiliogr 108(10):911\u2013917. https:\/\/doi.org\/10.1016\/j.ad.2017.07.002","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"5644_CR9","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.reuma.2017.08.007","volume":"14","author":"JC Torre Alonso","year":"2018","unstructured":"Torre Alonso JC, Diaz Del Campo Fontecha P, Almodovar R, Canete JD, Montilla Morales C, Moreno M et al (2018) Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. Reumatol Clin (Engl Ed) 14(5):254\u2013268. https:\/\/doi.org\/10.1016\/j.reuma.2017.08.007","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"6","key":"5644_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"key":"5644_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H et al (2024) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2024-225531","journal-title":"Ann Rheum Dis"},{"key":"5644_CR12","unstructured":"Haddaway NRAUPCC, McGuinness LA (2021) PRISMA2020: R package and ShinyApp for producing PRISMA 2020 compliant flow diagrams (Version 0.0.2). Zenodo"},{"issue":"10","key":"5644_CR13","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG (2013) Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys. JAMA Dermatol 149(10):2003\u20132011. https:\/\/pubmed.ncbi.nlm.nih.gov\/23945732\/. https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/1729130\/doi130034.pdf","journal-title":"JAMA Dermatol"},{"issue":"4","key":"5644_CR14","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN et al (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 80(4):1073\u20131113. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.058","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"5644_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2007.06.042","volume":"57","author":"EJ Horn","year":"2007","unstructured":"Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M (2007) Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 57(6):957\u2009\u2013\u200962. https:\/\/doi.org\/10.1016\/j.jaad.2007.06.042.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"5644_CR16","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/09546634.2018.1443200","volume":"29","author":"MLF Knuckles","year":"2018","unstructured":"Knuckles MLF, Levi E, Soung J (2018) Defining and treating moderate plaque psoriasis: a dermatologist survey. J Dermatolog Treat 29(7):658\u2009\u2013\u200963. https:\/\/doi.org\/10.1080\/09546634.2018.1443200.","journal-title":"J Dermatolog Treat"},{"key":"5644_CR17","doi-asserted-by":"crossref","unstructured":"Kulkarni AS, Horn E, Balkrishnan R, Feldman S (eds) Severity levels in psoriasis: a separate \u2018very severe\u2019 category not required. J Dermatol Treat. 1 ed. England 2009. pp. 48\u201351","DOI":"10.1080\/09546630802232807"},{"issue":"1","key":"5644_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"G Work","year":"2011","unstructured":"American Academy of Dermatology, Work G, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM et al (2011) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect.\u00a06. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 65(1):137\u2013174. https:\/\/doi.org\/10.1016\/j.jaad.2010.11.055","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5644_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40744-018-0135-1","volume":"6","author":"JF Merola","year":"2019","unstructured":"Merola JF, Shrom D, Eaton J, Dworkin C, Krebsbach C, Shah-Manek B et al (2019) Patient perspective on the Burden of skin and joint symptoms of psoriatic arthritis: results of a multi-national patient survey. Rheumatol Ther 6(1):33\u201345. https:\/\/doi.org\/10.1007\/s40744-018-0135-1","journal-title":"Rheumatol Ther"},{"issue":"2","key":"5644_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1515\/sjdv-2016-0006","volume":"8","author":"ZP Miju\u0161kovi\u0107","year":"2016","unstructured":"Miju\u0161kovi\u0107 ZP, Kandolf-Sekulovi\u0107 L, Tiodorovi\u0107 D, Nikoli\u0107 M, Jovanovi\u0107 M, \u0160kiljevi\u0107 D et al (2016) Serbian association of dermatovenereologists\u2019 guidelines for the diagnosis and treatment of psoriasis. Serb J Dermatol Venerol 8(2):61\u201378. https:\/\/www.embase.com\/search\/results?subaction=viewrecord&id=L616473783&from=export U2 - L616473783","journal-title":"Serb J Dermatol Venerol"},{"issue":"Suppl 10","key":"5644_CR21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/acr.24242","volume":"72","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Mease P (2020) Measuring outcomes in Psoriatic Arthritis. Arthritis Care Res (Hoboken) 72(Suppl 10):82\u2013109. https:\/\/doi.org\/10.1002\/acr.24242","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"5644_CR22","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/acr.22653","volume":"67","author":"HD Wilson","year":"2015","unstructured":"Wilson HD, Mutebi A, Revicki DA, Mease PJ, Genovese MC, Erondu N et al (2015) Reliability and validity of the Psoriasis Symptom Inventory in patients with psoriatic arthritis. Arthritis Care Res (Hoboken) 67(12):1750\u20131756. https:\/\/doi.org\/10.1002\/acr.22653","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"5644_CR23","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1111\/jdv.15983","volume":"33","author":"S Cazzaniga","year":"2019","unstructured":"Cazzaniga S, Anzengruber F, Augustin M, Boehncke WH, Borradori L, Conrad C et al (2019) Linkage between patients\u2019 characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for targeted therapies registry. J Eur Acad Dermatol Venereol 33(12):2313\u20132318. https:\/\/pubmed.ncbi.nlm.nih.gov\/31562785\/. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/jdv.15983","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5644_CR24","unstructured":"EMEA. Committee for medical products for human use of EMEA Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. European Medicines Agency Evaluation of Medicines for Human use, UEMEA\/CHMP\/EWP\/2454\/02 2004 [Available from: http:\/\/www.euma.europa.eu\/"},{"issue":"10","key":"5644_CR25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.autrev.2015.05.010","volume":"14","author":"E Lubrano","year":"2015","unstructured":"Lubrano E, Cantini F, Costanzo A, Girolomoni G, Prignano F, Olivieri I et al (2015) Measuring psoriatic disease in clinical practice. An expert opinion position paper. Autoimmun Rev 14(10):864\u2009\u2013\u200974. https:\/\/doi.org\/10.1016\/j.autrev.2015.05.010.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"5644_CR26","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/acr.24046","volume":"72","author":"PS Helliwell","year":"2020","unstructured":"Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S et al (2020) Composite measures of Disease Activity in Psoriatic Arthritis: comparative instrument performance based on the efficacy of Guselkumab in an interventional phase II trial. Arthritis Care Res (Hoboken) 72(11):1579\u20131588. https:\/\/doi.org\/10.1002\/acr.24046","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"5644_CR27","doi-asserted-by":"publisher","first-page":"105296","DOI":"10.1016\/j.jbspin.2021.105296","volume":"89","author":"HH Gezer","year":"2022","unstructured":"Gezer HH, Duru\u00f6z MT, Nas K, K\u0131l\u0131\u00e7 E, Sarg\u0131n B, Kasman SA et al (2022) Inconsistencies of the Disease Activity Assessment Tools for Psoriatic Arthritis: challenges to rheumatologists. Joint Bone Spine 89(3):105296. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105296","journal-title":"Joint Bone Spine"},{"issue":"1","key":"5644_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s12026-016-8843-5","volume":"65","author":"M Benucci","year":"2017","unstructured":"Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V et al (2017) Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res 65(1):419\u2013422. https:\/\/doi.org\/10.1007\/s12026-016-8843-5","journal-title":"Immunol Res"},{"issue":"9","key":"5644_CR29","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s10067-014-2626-y","volume":"33","author":"ML Acosta Felquer","year":"2014","unstructured":"Acosta Felquer ML, Ferreyra Garrott L, Marin J, Catay E, Scolnik M, Scaglioni V et al (2014) Remission criteria and activity indices in psoriatic arthritis. Clin Rheumatol 33(9):1323\u20131330. https:\/\/doi.org\/10.1007\/s10067-014-2626-y","journal-title":"Clin Rheumatol"},{"issue":"4","key":"5644_CR30","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s11926-010-0109-y","volume":"12","author":"A Mumtaz","year":"2010","unstructured":"Mumtaz A, FitzGerald O (2010) Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice. Curr Rheumatol Rep 12(4):264\u2009\u2013\u200971. https:\/\/doi.org\/10.1007\/s11926-010-0109-y.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"5644_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/ard.2010.129379","volume":"70","author":"A Mumtaz","year":"2011","unstructured":"Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD et al (2011) Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70(2):272\u2013277. https:\/\/doi.org\/10.1136\/ard.2010.129379","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5644_CR32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","volume":"76","author":"D Aletaha","year":"2017","unstructured":"Aletaha D, Alasti F, Smolen JS (2017) Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression. Ann Rheum Dis 76(2):418\u201321. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209511.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5644_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/rheumatology\/kez202","volume":"59","author":"JZ Fei","year":"2020","unstructured":"Fei JZ, Perruccio AV, Ye JY, Gladman DD, Chandran V (2020) The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. Rheumatology (Oxford) 59(1):69\u201376. https:\/\/doi.org\/10.1093\/rheumatology\/kez202","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"5644_CR34","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1136\/annrheumdis-2018-213463","volume":"77","author":"B Michelsen","year":"2018","unstructured":"Michelsen B, Sexton J, Smolen JS, Aletaha D, Krogh NS, van der Heijde D et al (2018) Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints? Ann Rheum Dis 77(12):1736\u20131741. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213463","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5644_CR35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS (2016) Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 75(5):811\u2013818. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207507","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5644_CR36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/rheumatology\/key004","volume":"57","author":"MM Schoels","year":"2018","unstructured":"Schoels MM, Landesmann U, Alasti F, Baker D, Smolen JS, Aletaha D (2018) Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. Rheumatology (Oxford) 57(6):969\u2013976. https:\/\/doi.org\/10.1093\/rheumatology\/key004","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5644_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3899\/jrheum.160924","volume":"44","author":"M Di Carlo","year":"2017","unstructured":"Di Carlo M, Becciolini A, Lato V, Crotti C, Favalli EG, Salaffi F (2017) The 12-item psoriatic arthritis impact of Disease Questionnaire: construct validity, reliability, and interpretability in a clinical setting. J Rheumatol 44(3):279\u2013285. https:\/\/doi.org\/10.3899\/jrheum.160924","journal-title":"J Rheumatol"},{"issue":"6","key":"5644_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/acr.24134","volume":"72","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A et al (2020) Treatment-to-target with apremilast in psoriatic arthritis: the probability of achieving targets and Comprehensive Control of Disease manifestations. Arthritis Care Res (Hoboken) 72(6):814\u201321. https:\/\/doi.org\/10.1002\/acr.24134.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"5644_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13075-017-1424-8","volume":"19","author":"LJJ van Mens","year":"2017","unstructured":"van Mens LJJ, van de Sande MGH, Fluri IA, Atiqi S, van Kuijk AWR, Baeten DLP (2017) Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice. Arthritis Res Ther 19(1):226. https:\/\/doi.org\/10.1186\/s13075-017-1424-8","journal-title":"Arthritis Res Ther"},{"key":"5644_CR40","doi-asserted-by":"crossref","unstructured":"Mulder MLM, van Hal TW, van den Hoogen FHJ, de Jong E, Vriezekolk JE, Wenink MH (2020) Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden. Rheumatology (Oxford). 00, https:\/\/pubmed.ncbi.nlm.nih.gov\/33331947\/","DOI":"10.1093\/rheumatology\/keaa766"},{"key":"5644_CR41","doi-asserted-by":"publisher","first-page":"353657","DOI":"10.1155\/2015\/353657","volume":"2015","author":"P Naranje","year":"2015","unstructured":"Naranje P, Prakash M, Sharma A, Dogra S, Khandelwal N (2015) Ultrasound findings in hand joints involvement in patients with psoriatic arthritis and its correlation with clinical DAS28 score. Radiol Res Pract 2015:353657. https:\/\/doi.org\/10.1155\/2015\/353657","journal-title":"Radiol Res Pract"},{"issue":"11","key":"5644_CR42","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s00296-012-2534-x","volume":"33","author":"GT Sakellariou","year":"2013","unstructured":"Sakellariou GT, Sayegh FE, Anastasilakis AD, Kapetanos GA (2013) Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int 33(11):2917\u20132920. https:\/\/doi.org\/10.1007\/s00296-012-2534-x","journal-title":"Rheumatol Int"},{"key":"5644_CR43","doi-asserted-by":"crossref","unstructured":"Coates LC, Mumtaz A, Helliwell PS, Mease PJ, Callis-Duffin K, Krueger GG et al (eds) (2011) Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. J Rheumatol; Canada","DOI":"10.3899\/jrheum.110278"},{"issue":"2","key":"5644_CR44","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3899\/jrheum.090956","volume":"37","author":"DD Gladman","year":"2010","unstructured":"Gladman DD, Landewe R, McHugh NJ, Fitzgerald O, Thaci D, Coates L et al (2010) Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol 37(2):453\u201361. https:\/\/doi.org\/10.3899\/jrheum.090956.","journal-title":"J Rheumatol"},{"key":"5644_CR45","doi-asserted-by":"publisher","unstructured":"Helliwell PS, Fitzgerald O, Strand CV, Mease PJ (2011) Composite Measures in Psoriatic Arthritis: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 38(3):540\u20135; https:\/\/doi.org\/10.3899\/jrheum.101116","DOI":"10.3899\/jrheum.101116"},{"key":"5644_CR46","doi-asserted-by":"crossref","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH et al (eds) (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis","DOI":"10.1136\/ard.2008.094946"},{"issue":"1","key":"5644_CR47","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","volume":"20","author":"LC Coates","year":"2018","unstructured":"Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK et al (2018) Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther 20(1):272. https:\/\/doi.org\/10.1186\/s13075-018-1773-y","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"5644_CR48","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3899\/jrheum.140172","volume":"41","author":"PS Helliwell","year":"2014","unstructured":"Helliwell PS, FitzGerald O, Fransen J (2014) Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol 41(6):1212\u20131217. https:\/\/doi.org\/10.3899\/jrheum.140172","journal-title":"J Rheumatol"},{"issue":"3","key":"5644_CR49","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3899\/jrheum.181472","volume":"47","author":"AV Perruccio","year":"2020","unstructured":"Perruccio AV, Got M, Li S, Ye Y, Gladman DD, Chandran V (2020) Treating Psoriatic Arthritis to Target: defining the psoriatic arthritis disease activity score that reflects a state of Minimal Disease Activity. J Rheumatol 47(3):362\u2013368. https:\/\/pubmed.ncbi.nlm.nih.gov\/31203221\/. https:\/\/www.jrheum.org\/content\/jrheum\/47\/3\/362.full.pdf","journal-title":"J Rheumatol"},{"issue":"11","key":"5644_CR50","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3899\/jrheum.201195","volume":"48","author":"DD Gladman","year":"2021","unstructured":"Gladman DD, Starr M, Cividino A, Gaudreau AJ, Jelley J, Nicholson D et al (2021) Canadian rheumatologists\u2019 perspectives on moderate psoriatic arthritis and Oligoarticular Psoriatic Arthritis. J Rheumatol 48(11):1692\u20131697. https:\/\/doi.org\/10.3899\/jrheum.201195","journal-title":"J Rheumatol"},{"key":"5644_CR51","doi-asserted-by":"crossref","unstructured":"Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY et al (eds) (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect.\u00a02. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol; United States","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"5644_CR52","doi-asserted-by":"publisher","unstructured":"Salgado-Boquete L, Carrascosa JM, Llamas-Velasco M, Ruiz-Villaverde R, de la Cueva P, Belinchon I (2021) A New Classification of the Severity of Psoriasis: What\u2019s Moderate Psoriasis? Life (Basel) 11(7). https:\/\/doi.org\/10.3390\/life11070627","DOI":"10.3390\/life11070627"},{"issue":"10","key":"5644_CR53","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3899\/jrheum.160904","volume":"44","author":"AM Orbai","year":"2017","unstructured":"Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W et al (2017) Updating the Psoriatic Arthritis (PsA) Core Domain Set: a report from the PsA Workshop at OMERACT 2016. J Rheumatol 44(10):1522\u20131528. https:\/\/doi.org\/10.3899\/jrheum.160904","journal-title":"J Rheumatol"},{"issue":"12","key":"5644_CR54","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1136\/annrheumdis-2015-208509","volume":"74","author":"PS Helliwell","year":"2015","unstructured":"Helliwell PS, Coates LC (2015) The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains? Ann Rheum Dis 74(12):e66. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208509","journal-title":"Ann Rheum Dis"},{"key":"5644_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3899\/jrheum.200121","volume":"96","author":"W Tillett","year":"2020","unstructured":"Tillett W, McHugh N, Orbai AM, Ogdie A, Leung YY, Coates LC et al (2020) Outcomes of the 2019 GRAPPA Workshop on continuous composite indices for the Assessment of Psoriatic Arthritis and Membership-recommended next steps. J Rheumatol Suppl 96:11\u201318. https:\/\/doi.org\/10.3899\/jrheum.200121","journal-title":"J Rheumatol Suppl"},{"issue":"4","key":"5644_CR56","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.semarthrit.2021.04.018","volume":"51","author":"D Benavent","year":"2021","unstructured":"Benavent D, Plasencia C, Poddubnyy D, Kishimoto M, Proft F, Sawada H et al (2021) Unveiling axial involvement in psoriatic arthritis: an ancillary analysis of the ASAS-perSpA study. Semin Arthritis Rheum 51(4):766\u201374. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.04.018.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"5644_CR57","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1093\/rheumatology\/kez457","volume":"59","author":"J Feld","year":"2020","unstructured":"Feld J, Ye JY, Chandran V, Inman RD, Haroon N, Cook R et al (2020) Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology (Oxford) 59(6):1340\u20131346. https:\/\/doi.org\/10.1093\/rheumatology\/kez457","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5644_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.rdc.2020.01.009","volume":"46","author":"X Michelena","year":"2020","unstructured":"Michelena X, Poddubnyy D, Marzo-Ortega H (2020) Axial psoriatic arthritis: a distinct clinical entity in search of a definition. Rheum Dis Clin North Am 46(2):327\u201341. https:\/\/doi.org\/10.1016\/j.rdc.2020.01.009.","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"5644_CR59","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","volume":"51","author":"D Poddubnyy","year":"2021","unstructured":"Poddubnyy D, Jadon DR, Van den Bosch F, Mease PJ, Gladman DD (2021) Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheum 51(4):880\u2013887. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.06.006","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"5644_CR60","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.reumae.2022.03.008","volume":"19","author":"J Gratac\u00f3s","year":"2023","unstructured":"Gratac\u00f3s J, Pablos JL, de Miguel E, Juanola X, Fern\u00e1ndez-Carballido C, Ariza R et al (2023) Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study. Reumatol Clin (Engl Ed) 19(4):204\u2013210. https:\/\/doi.org\/10.1016\/j.reumae.2022.03.008","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"11","key":"5644_CR61","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3899\/jrheum.191056","volume":"47","author":"JD Ca\u00f1ete","year":"2020","unstructured":"Ca\u00f1ete JD, Nolla JM, Queiro R, Rodr\u00edguez MJ, Ruiz M, Liz\u00e1n L (2020) Expert Consensus on a set of outcomes to assess the effectiveness of Biologic Treatment in Psoriatic Arthritis: the MERECES Study. J Rheumatol 47(11):1637\u20131643. https:\/\/doi.org\/10.3899\/jrheum.191056","journal-title":"J Rheumatol"},{"issue":"6","key":"5644_CR62","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jclinepi.2013.12.009","volume":"67","author":"SR Johnson","year":"2014","unstructured":"Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M et al (2014) Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. J Clin Epidemiol 67(6):706\u201314. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.12.009.","journal-title":"J Clin Epidemiol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05644-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05644-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05644-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T15:09:26Z","timestamp":1732374566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05644-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["5644"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05644-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"16 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest related to the study\u2019s subject.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}